Lonza's Major Move: Purchase of Biologics Facility from Roche in California
Lonza's Strategic Acquisition
Swiss contract drug manufacturer Lonza has made a decisive move by agreeing to purchase a substantial biologics manufacturing site in California from Roche. This acquisition, valued at $1.2 billion, signifies Lonza's commitment towards expanding its foothold in the biopharmaceutical domain.
Enhancing Capabilities and Market Presence
Lonza's strategic purchase of the biologics facility from Roche is aimed at bolstering its capabilities and market presence, particularly in the United States. This acquisition is set to propel Lonza into a stronger position in the global biologics market.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.